Peptide safety
"Is this safe?" is the right first question. These articles look at peptide safety — what data actually exists for peptides and GLP-1 medications: what trials measured, what has only been studied in animals, how sourcing and compounding affect quality, and which red flags matter when you read claims online.
The prescription requirement exists precisely for this: a licensed provider weighs your health history before anything ships — and can say no. The same standard applies across the site: what a study measured, in whom, and for how long.
227 articles on this topic
-
Is Semaglutide FDA Approved? Not When Compounded
Promise dispenses semaglutide as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. Ozempic, Rybelsus and Wegovy have approvals for specific uses.
-
NAD Injection Dosage: What Human Studies Used
There is no validated subcutaneous or intramuscular NAD+ schedule. The best-known IV pharmacokinetic study used 750 mg over six hours, so a prescriber must set route, concentration, amount and frequency together.
-
Peptides for Joint Pain: What the Evidence Shows
Peptides for joint pain are being studied, but the evidence is mostly cell and animal work. One uncontrolled 16-person knee follow-up is not enough to show that BPC-157, TB-500 or their combination repairs human joints.
-
Semaglutide and Pregnancy: What the Evidence Says
Semaglutide is not recommended for routine weight management during pregnancy. The label calls for a two-month gap before planned conception, while early human exposure data remain limited rather than conclusive.
-
Tesamorelin vs Ipamorelin: What Sets Them Apart
Both peptides signal the pituitary to release growth hormone, but they use different receptors and carry very different levels of human evidence. Tesamorelin has phase 3 trial data; ipamorelin does not.
-
Tirzepatide and Birth Control: The 4-Week Rule
Tirzepatide may reduce the absorption of birth control taken by mouth. The current U.S. labels advise non-oral contraception or an added barrier method for four weeks after starting and after every dose increase.
-
Tirzepatide Benefits: What the Trials Show
Tirzepatide benefits are best established for weight reduction and blood-sugar control, with a branded indication for moderate-to-severe sleep apnea in adults with obesity. Heart failure, liver, blood-pressure and lipid findings are promising but narrower.
-
BPC-157 for Tendonitis: What the Evidence Shows
The tendon case for BPC-157 comes from cells and rats, not randomized human trials. Here is what those studies can tell us, what they cannot, and why rehabilitation still matters.
-
Is Tirzepatide FDA Approved? Not When Compounded
Tirzepatide has branded approvals under Mounjaro and Zepbound. A compounded preparation is different from an FDA-approved product: the formulation offered here is not FDA-approved.
-
Semaglutide Constipation: What Helps
Semaglutide constipation is common during initiation and dose escalation. It usually eases, but it can last longer than other stomach side effects and deserves a clear plan with the prescriber.
-
Sermorelin for Women: Evidence and Menopause
Sermorelin can raise growth-hormone output in women when the pituitary responds, but female-specific trials are small and mostly use related GHRH compounds. It is not menopause hormone therapy, and the evidence does not show reliable gains in sleep, libido or lean mass for women.
-
Tirzepatide Long-Term Side Effects: 3-Year Data
Three-year weight-management data and four-year cardiovascular data have not revealed a new late safety signal. They also do not tell us what decades of exposure will look like.
-
Are Peptides Legal in the US? What the Law Says
Prescription peptides can be lawful when a licensed provider prescribes them and an authorized pharmacy dispenses them under federal and state rules. A compounded medication, an approved drug and a grey-market vial do not share the same legal status.
-
Epitalon Dosage: How a Prescriber Decides
Published evidence does not establish a standard dose. One small human AEDG study used 0.5 mg daily under the tongue for 20 days; injection-cycle numbers often come from animal work or studies of a different pineal extract.
-
How to Store Peptides: Fridge, Freezer, and Travel
Reconstituted peptide vials are commonly refrigerated at 2–8 °C, but the pharmacy label and beyond-use date always control. Lyophilized powders and commercial pens may have different limits.
-
Oral BPC-157: Do Capsules Work?
Oral activity has been reported in rat gut models, but capsules have not been tested in human trials and their absorption in people has not been measured. A capsule label cannot close that evidence gap.
-
PT-141 Side Effects: What the Trials Found
PT-141 most often causes nausea, flushing, headache, and injection-site reactions. The safety questions that change screening are blood-pressure effects, skin darkening, and how little modern evidence exists for men.
-
How Often Do You Inject Peptides?
Injection frequency can range from nightly to once weekly because each peptide has a different half-life, mechanism, and formulation. The prescription label for the exact vial sets the schedule.
-
Peptides for Autoimmune Disease: The Evidence
Thymosin Alpha-1 has meaningful human immune-modulation research, while KPV remains mostly a cell-and-animal finding; neither has clinical evidence that makes it an autoimmune treatment.
-
Does Semaglutide Cause Muscle Loss?
Semaglutide-related weight loss can include a drop in lean mass, but DXA lean mass is not the same as skeletal muscle. STEP 1 found fat fell faster than lean tissue, improving lean mass as a share of body weight.
Page 9 of 12 · 227 articles